Neurokinin-1 receptor antagonists: a comprehensive patent survey

Bibliography

• Snider RM, Constantine JW, Lowe JA III, A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991;251:435-7
   PubMed Web of Science ®Google Scholar
• McLean S, Ganong AH, Seeger TF, Activity and distribution of binding sites in brain of a nonpeptide substance P (NK1) receptor antagonist. Science 1991;251:437-9
   PubMed Web of Science ®Google Scholar
• Pennefather JN, Lecci A, Candenas ML, Tachykinins and tachykinin receptors: a growing family. Life Sci 2004;74:1445-63
   PubMed Web of Science ®Google Scholar
• Page NM. New challenges in the study of the mammalian tachykinins. Peptides 2005;26:1356-68
   PubMedGoogle Scholar
• Patacchini R, Maggi CA. Peripheral tachykinin receptors as targets for new drugs. Eur J Pharmacol 2001;429:13-21
   PubMed Web of Science ®Google Scholar
• Patacchini R, Lecci A, Holzer P, Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci 2004;25:1-3
   PubMed Web of Science ®Google Scholar
• Huang RR, Yu H, Strader CD, Interaction of substance P with the second and seventh transmembrane domains of the neurokinin-1 receptor. Biochemistry 1994;33:3007-13
   PubMedGoogle Scholar
• Holzer P. Tachykinins: handbook of experimental pharmacology. Volume 164. Springer-Verlag, Berlin, Heidelberg; 2004
   Google Scholar
• Duffy RA. Potential therapeutic target for neurokinin receptor antagonists. Expert Opin Emerg Drugs 2004;9:9-21
   PubMedGoogle Scholar
• Luo W, Sharif TR, Sharif M. Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway. Cancer Res 1996;56:4983-91
   PubMed Web of Science ®Google Scholar
• Palma C, Nardelli F, Manzini S, Substance P activates responses correlated with tumour growth in human glioma cell lines bearing tachykinin NK1 receptors. Br J Cancer 1999;79:236-43
   PubMed Web of Science ®Google Scholar
• Munoz M, Perez A, Rosso M, Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res 2004;14:183-8
   PubMed Web of Science ®Google Scholar
• Munoz M, Rosso M, Covenas R. The NK-1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines. Lett Drug Des Discov 2006;3:323-9
   Web of Science ®Google Scholar
• Seckl MJ, Higgins T, Widmer F, [D-Arg1,D-Trp5,7,9,Leu11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997;57:51-4
   PubMed Web of Science ®Google Scholar
• Palma C, Bigioni M, Irrissuto C, Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer 2000;82:480-7
   PubMed Web of Science ®Google Scholar
• Reddy BY, Trzaska KA, Murthy RG, Neurokinin receptors as potential targets in breast cancer treatment. Curr Drug Discov Technol 2008;5:15-9
   PubMedGoogle Scholar
• Astrazeneca AB. Preparation of cyclized benzamide ([1,5]oxazocines) as neurokinin antagonists for use in therapy. WO02026724; 2002
   Google Scholar
• Astrazeneca AB. Preparation of internally cyclized naphthamides as neurokinin antagonists for use as medicaments. WO01077089; 2001
   Google Scholar
• Astrazeneca AB. Preparation of N-(2-phenyl-3-aminocarbonyl-propyl)-1-naphthamides as neurokinin antagonists for use as medicaments. WO01077069; 2001
   Google Scholar
• Astrazeneca AB. Preparation of N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonist. WO00059873; 2000
   Google Scholar
• Ohnmacht CJ, Albert JS, Bernstein PR, Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists. Bioorg Med Chem 2004;12:2653-69
   PubMedGoogle Scholar
• Boehringer Ingelheim KG. Preparation of arylglycinamide derivatives as tachykinin antagonists. DE19519245; 1996
   Google Scholar
• Boehringer Ingelheim KG. Novel arylglycinamide derivatives, processes for their preparation, and pharmaceutical compositions containing them as neurokinin antagonists. WO9732865; 1997
   Google Scholar
• Boehringer Ingelheim KG. Method using NK1 receptor antagonists for the treatment or prevention of atopic dermatitis. EP1295599; 2003
   Google Scholar
• Ciba-Geigy AG.Preparation of 1-acylpiperidine derivatives and their use as substance P antagonists. EP532456; 1993
   Google Scholar
• Ofner S, Hauser K, Schilling W, SAR of 2-benzyl-4-aminopiperidines: CGP 49823, an orally and centrally active non-peptide NK1 antagonist. Bioorg Med Chem Lett 1996;6:1623-8
   Web of Science ®Google Scholar
• Ciba-Geigy AG. Preparation of aryl/heteroaryl-substituted acylaminoalkanecarboxamides and acylaminoalkenecarboxamides as neurokinin 1 antagonists. WO9626183; 1996
   Google Scholar
• Ciba-Geigy AG. Preparation of 1-acyl-4-[acylamino(methyl)]piperidines and analogs as substance P antagonists. WO9610562; 1996
   Google Scholar
• Eli Lilly. Non-peptide tachykinin receptor antagonists. WO9514017; 1995
   Google Scholar
• Eli Lilly. 2-acylaminopropanamines as tachykinin receptor antagonists. WO9907681; 1999
   Google Scholar
• Hipskind PA, Howbert JJ, Bruns RF, 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 1996;39:736-48
   PubMedGoogle Scholar
• Goldstein DJ, Wang O, Saper JR, Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997;17:785-90
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Wang O, Todd LE, Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 2000;67:419-26
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Wang O, Gitter BD, Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 2001;24:16-22
   PubMed Web of Science ®Google Scholar
• Eli Lilly. Preparation of triazole derivatives as tachykinin receptor antagonists. WO03091226; 2003
   Google Scholar
• Tauscher J, Kielbasa W, Iyengar S, Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol 2010;20:80-7
   PubMed Web of Science ®Google Scholar
• George DT, Gilman J, Hersh J, Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 2008;319:1536-9
   PubMed Web of Science ®Google Scholar
• Fujisawa. Preparation of acyldipeptide amides as tachykinin antagonists. EP394989; 1990
   Google Scholar
• Fujisawa. Preparation of prolylnaphthylalaninamides as tachykinin antagonists. EP443132; 1991
   Google Scholar
• Fujisawa. Peptides with tachykinin antagonist activity. WO9222569; 1992
   Google Scholar
• Fujisawa. Preparation of peptides with tachykinin antagonist activity. WO9314113; 1993
   Google Scholar
• Fujisawa. Peptides having substance P antagonistic activity. WO9321215; 1993
   Google Scholar
• Fujisawa. Preparation of piperazine-derivative tachykinin antagonists. EP655442; 1995
   Google Scholar
• Fujisawa. Piperazine derivatives useful as tachykinin antagonists. WO9637488; 1996
   Google Scholar
• Takaya T. Discovery of neurokinin antagonists. Pure Appl Chem 1996;68:875-80
   Google Scholar
• Hagiwara D, Miyake H, Igari N, Studies on neurokinin antagonists. 4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists: N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N- methyl-N-(phenylmethyl)-3-(2-naphthyl)-L-alaninamide and its related compounds. J Med Chem 1994;37:2090-9
   PubMedGoogle Scholar
• Ichinose M, Miura M, Yamauchi H, A neurokinin 1-receptor antagonist improves exercise-induced airway narrowing in asthmatic patients. Am J Respir Crit Care Med 1996;153:936-41
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Preparation of 3-(5-tetrazolylbenzyl)piperidinamine derivatives as tachykinin antagonists. WO9508549; 1995
   Google Scholar
• GlaxoSmithKline. Preparation of 3-(tetrazolylbenzylamino)-2-phenylpiperidines as neurokinin antagonists. WO9629326; 1996
   Google Scholar
• GlaxoSmithKline. Preparation of 2-phenylpiperazine-1-carboxylic acid benzylamides as tachykinin antagonists. WO01025219; 2001
   Google Scholar
• Armour DR, Chung KML, Congreve M, Tetrazole NK1 receptor antagonists: the identification of an exceptionally potent orally active antiemetic compound. Bioorg Med Chem Lett 1996;6:1015-20
   Google Scholar
• Reid K, Palmer JL, Wright RJ, Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man. Br J Clin Pharmacol 2000;50:61-4
   PubMed Web of Science ®Google Scholar
• Brocco M, Dekeyne A, Mannoury la Cour C, Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 2008;18:729-50
   PubMedGoogle Scholar
• GlaxoSmithKline. Preparation of 2-phenyl-4-piperazinylpiperidine-1-carboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders. WO02032867; 2002
   Google Scholar
• GlaxoSmithKline. Combinations of paroxetine and 2-(R)-(4-fluoro-2-methylphenyl)-4-(S)-((8aS)-6-oxohexahydropyrrolo[1,2-a]pyrazin-2-yl)piperidine-1-carboxylic acid [1-(R)-(3,5-bistrifluoromethylphenyl)ethyl]methylamide for treatment of depression/anxiety. WO04091615; 2004
   Google Scholar
• GlaxoSmithKline. Preparation of carbamoylpiperazine derivatives as NK1 receptor antagonists. WO08046882; 2008
   Google Scholar
• Hoffmann-La Roche. Preparation of biphenyl derivatives as antagonists of the neurokinin-1 receptor. WO00053572; 2000
   Google Scholar
• Hoffmann-La Roche. Preparation of N-benzyl-4-tolylnicotinamides and related compounds as neurokinin-1 receptor antagonists. EP1035115; 2000
   Google Scholar
• Hoffmann-La Roche. Process for preparation of pyridine derivatives. EP1103546; 2001
   Google Scholar
• Hoffmann-La Roche. Preparation of 4-phenylpyridine derivatives as neurokinin-1 receptor antagonists. WO02008232; 2002
   Google Scholar
• Hoffmann-La Roche. Preparation of aryl substituted N-acylpiperidine derivatives as neurokinin 1 antagonists. WO02062784; 2002
   Google Scholar
• Hoffmann T, Bos M, Stadler H, Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett 2006;16:1362-5
   PubMed Web of Science ®Google Scholar
• Janssen. 1-(1,2-Disubstituted piperidinyl)-4-(fused imidazole)piperidine derivatives useful as substance P antagonists. WO9724356; 1997
   Google Scholar
• Janssen. Preparation of 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives as substance-P antagonists. WO9716440; 1997
   Google Scholar
• Janssen. Use of substance P antagonists for influencing the circadian timing system. WO01030348; 2001
   Google Scholar
• Janssen. Drug combinations comprising opioid analgesics and 1-(1,2-disubstituted piperidinyl)-4-substituted piperazines and preparation of the latter. WO04110451; 2004
   Google Scholar
• Megens AA, Ashton D, Vermeire JC, Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther 2002;302:696-709
   PubMedGoogle Scholar
• Romerio SC, Linder L, Haefeli WE. Neurokinin-1 receptor antagonist R116301 inhibits substance P-induced venodilation. Clin Pharmacol Ther 1999;66:522-7
   PubMedGoogle Scholar
• Merck. Preparation of 2-amino-1-benzyloxy-3,3-diphenylpropanes and analogs as tachykinin antagonists. EP522808; 1993
   Google Scholar
• Teall M, Harrison T, Moseley JD, Linear amides as substance P antagonists. Bioorg Med Chem Lett 1996;6:1585-8
   Google Scholar
• Munoz M, Perez A, Covenas R, Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines. Arch Ital Biol 2004;142:105-12
   PubMed Web of Science ®Google Scholar
• Munoz M, Rosso M, Perez A, Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2005;46:2567-70
   PubMed Web of Science ®Google Scholar
• Munoz M, Rosso M, Aguilar FJ, NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 2008;26:111-8
   PubMed Web of Science ®Google Scholar
• Rosso M, Robles-Frias MJ, Covenas R, The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 2008;29:245-54
   PubMedGoogle Scholar
• Harrison T, Owens AP, Williams BJ, Piperidine-ether based hNK1 antagonists 2: investigation of the effect of N-substitution. Bioorg Med Chem Lett 1995;5:209-12
   Google Scholar
• Ladduwahetty T, Baker R, Cascieri MA, N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. J Med Chem 1996;39:2907-14
   PubMedGoogle Scholar
• Hale JJ, Mills SG, MacCoss M, 2(S)-((3,5-bis(trifluoromethyl)benzyl)-oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. J Med Chem 1996;39:1760-2
   PubMed Web of Science ®Google Scholar
• Hale JJ, Mills SG, MacCoss M, Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 1998;41:4607-14
   PubMed Web of Science ®Google Scholar
• Available from: www.fda.gov
   Google Scholar
• Zhao MM, McNamara JM, Ho GJ, Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction. J Org Chem 2002;67:6743-7
   PubMed Web of Science ®Google Scholar
• Elati CR, Kolla N, Gangula S, A convergent approach to the synthesis of aprepitant: a potent human NK-1 receptor antagonist. Tetrahedron Lett 2007;48:8001-4
   Google Scholar
• Merck. Preparation of diphenyloxaspiroalkanes as tachykinin receptor antagonists. WO9817660; 1998
   Google Scholar
• Merck. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists. US5929094; 1999
   Google Scholar
• Merck. Preparation of phenyl-spiro(cycloalkyl ethers) as tachykinin receptor antagonists. US5877191; 1999
   Google Scholar
• Merck. Preparation of novel substituted tetrahydropyrans as neurokinin 1 (NK-1) receptor antagonists. WO00056727; 2000
   Google Scholar
• Merck. Preparation of tetrahydropyran derivatives as NK-1 antagonists. WO04009573; 2004
   Google Scholar
• Merck. Preparation of 1-[(2-arylindol-3-yl)-1-oxoalkyl]piperazines as antagonists of tachykinins. WO00051984; 2000
   Google Scholar
• Merck. Synthesis of aryl-amido-cyclohexane derivatives and their use as NK-1 receptor antagonists. WO01087838; 2001
   Google Scholar
• Merck. Preparation of gem-disubstituted cyclohexane-containing azetidinones, pyrrolidinones and piperidinones as neurokinin 1 receptor antagonists and their use as therapeutic agents. WO02102372; 2002
   Google Scholar
• Merck. Preparation of substituted cyclopentyl zwitterionic tachykinin receptor antagonists. WO02024629; 2002
   Google Scholar
• Merck. Preparation of cyclopentyl gamma-lactams as tachykinin receptor antagonists. US20050282886; 2005
   Google Scholar
• Merck. Hydroisoindoline tachykinin receptor antagonists. US20050165083; 2005
   Google Scholar
• Merck. Preparation of 5-phenyl-5,6,7,8-tetrahydroquinolines as tachykinin receptor antagonists. WO06060344; 2006
   Google Scholar
• Merck. Preparation of 8-phenyl-5,6,7,8-tetrahydroquinolines as tachykinin receptor antagonists. WO06060346; 2006
   Google Scholar
• Merck. Preparation of octahydropyrano[3,4-c]pyrroles as tachykinin receptor antagonists. WO06065711; 2006
   Google Scholar
• Merck. Preparation of hexahydropyrano[3,4-c]pyrroles as tachykinin receptor antagonists. WO07075528; 2007
   Google Scholar
• Merck. Preparation of bis(trifluoromethyl)phenyl quinolines as tachykinin receptor antagonists. WO06060390; 2006
   Google Scholar
• Merck. Preparation of 5,6-fused pyrrolidine compounds as tachykinin receptor antagonists. WO07136570; 2007
   Google Scholar
• Merck. Preparation of therapeutic pyrrolopiperidine tachykinin and tachykinin receptor antagonists. WO09002770; 2009
   Google Scholar
• Novatis. Preparation of heterocyclyl prolyl(naphthyl)alaninamides as tachykinin antagonists. WO9831704; 1998
   Google Scholar
• Novratis. Preparation of aroylpiperidines as substance P antagonists. WO04024714; 2004
   Google Scholar
• Sindrup SH, Graf A, Sfikas N. The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain 2006;10:567-71
   PubMed Web of Science ®Google Scholar
• Vassout A, Veenstra S, Hauser K, NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul Pept 2000;96:7-16
   PubMed Web of Science ®Google Scholar
• El-Hashim AZ, Wyss D, Lewis C. Effect of a novel NK1 receptor selective antagonist (NKP608) on citric acid induced cough and airway obstruction. Pulm Pharmacol Ther 2004;17:11-8
   PubMed Web of Science ®Google Scholar
• Gerspacher M, La Vecchia L, Mah R, Dual neurokinin NK(1)/NK(2) antagonists: N-[(R,R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamides and 3-[N′-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N′-methylhydrazino]-N-[(R)-2-oxo-azepan-3-yl]propionamides. Bioorg Med Chem Lett 2001;11:3081-4
   PubMed Web of Science ®Google Scholar
• Novartis. Synthesis of acylaminoalkenylene amides useful as substance P antagonists. WO07118651; 2007
   Google Scholar
• Joos GF, Vincken W, Louis R, Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J 2004;23:76-81
   PubMed Web of Science ®Google Scholar
• Garret C, Carruette A, Fardin V, Pharmacological properties of a potent and selective nonpeptide substance P antagonist. Proc Natl Acad Sci USA 1991;88:10208-12
   PubMed Web of Science ®Google Scholar
• Lowe JA III, Drozda SE, Snider RM, The discovery of (2S,3S)-cis-2-(diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]-octan-3-amine as a novel, nonpeptide substance P antagonist. J Med Chem 1992;35:2591-600
   PubMed Web of Science ®Google Scholar
• Lowe JA III, Drozda SE, McLean S, Aza-tricyclic substance P antagonists. J Med Chem 1994;37:2831-40
   PubMedGoogle Scholar
• Desai MC, Lefkowitz SL, Thadeio PF, Discovery of a potent substance P antagonist: recognition of the key molecular determinant. J Med Chem 1992;35:4911-3
   PubMed Web of Science ®Google Scholar
• Rosen TJ, Coffman KJ, McLean S, Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist. Bioorg Med Chem Lett 1998;8:281-4
   PubMed Web of Science ®Google Scholar
• Shishido Y, Wakabayashi H, Koike H, Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist ‘CJ-17,493’. Bioorg Med Chem 2008;16:7193-205
   PubMed Web of Science ®Google Scholar
• Pfizer. Preparation of N-(isobenzofuranylmethyl)piperidinamines and analogs as substance P receptor antagonists. WO9925714; 1999
   Google Scholar
• Tsuchiva M, Fujiwara Y, Kanai Y, Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret. Pharmacology 2002;66:144-52
   PubMedGoogle Scholar
• Hesketh PJ, Gralla RJ, Webb RT, Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-43
   PubMed Web of Science ®Google Scholar
• Evangelista S. Ezlopitant. Pfizer. Curr Opin Investig Drugs 2001;2:1441-3
   PubMedGoogle Scholar
• Rhone-Poulenc Rorer. Preparation of 2-(phenylacetyl)-7,7-diphenylperhydroisoindol-4-ones and analogs as substance P antagonists. EP429366; 1991
   Google Scholar
• Rhone-Poulenc Rorer. Perhydroisoindoles, their preparation and pharmaceutical compositions containing them as substance P antagonists. EP514273; 1992
   Google Scholar
• Rhone-Poulenc Rorer. Preparation of thiopyranopyrrole derivatives as substance P antagonists. EP514275; 1992
   Google Scholar
• Rhone-Poulenc Rorer. Preparation of perhydroisoindoles as substance P antagonists. WO9321154; 1993
   Google Scholar
• Tabart M, Peyronel J-F. Synthesis of RPR 100893, prototype of a new series of potent and selective non peptide NK1 antagonists : the triarylperhydroisoindolols. Bioorg Med Chem Lett 1994;4:673-6
   Google Scholar
• Diener HC, RPR100893 Study Group. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 2003;23:183-5
   PubMedGoogle Scholar
• Sanofi-Aventis. Preparation of 1-aralk(ano)yl-3-aryl-3-(piperidinoalkyl)piperidines and analogs as substance P and neurokinin antagonists. EP512901; 1992
   Google Scholar
• Jung M, Calassi R, Maruani J, Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors. Neuropharmacology 1994;33:167-79
   PubMedGoogle Scholar
• Sanofi-Aventis. Preparation of N-(piperidyloxyalkyl)piperidines and analogs as neurokinin receptor antagonists. WO9526338; 1995
   Google Scholar
• Sanofi-Aventis. Preparation of novel morpholine derivatives and their affinity for human NK1 receptors of substance P. WO00058292; 2000
   Google Scholar
• Emonds-Alt X, Steinberg R, Oury-Donat F, SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 2002;303:1171-9
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrial.gov
   Google Scholar
• Schering-Plough. Preparation of bridged arylpiperidines as nk1 antagonists. WO06065654; 2006
   Google Scholar
• Shue HJ, Chen X, Schwerdt JH, Cyclic urea derivatives as potent NK1 selective antagonists. Part II: effects of fluoro and benzylic methyl substitutions. Bioorg Med Chem Lett 2006;16:1065-9
   PubMedGoogle Scholar
• Paliwal S, Reichard GA, Shah S, Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists. Bioorg Med Chem Lett 2008;18:4168-71
   PubMedGoogle Scholar
• Schering-Plough. Preparation of pyrrolidine and piperidine derivatives for therapeutic use as neurokinin 1 (NK1) receptor antagonists. WO03051840; 2003
   Google Scholar
• Takeda. Isoquinolone tachykinin and substance P receptor antagonists. EP566069; 1993
   Google Scholar
• Takeda. Preparation of phenylisoquinolinone derivatives as calcium- and substance P antagonists for treating cerebrovascular disorders. EP634402; 1995
   Google Scholar
• Natsugari H, Ikeura Y, Kiyota Y, Novel, potent, and orally active substance P antagonists: synthesis and antagonist activity of N-benzylcarboxamide derivatives of pyrido[3,4-b]pyridine. J Med Chem 1995;38:3106-20
   PubMed Web of Science ®Google Scholar
• Takeda.Preparation of tricyclic heterocyclic compounds as tachykinin receptor antagonists, and their intermediates. JP10259184; 1998
   Google Scholar
• Natsugari H, Ikeura Y, Kamo I, Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions. J Med Chem 1999;42:3982-93
   PubMed Web of Science ®Google Scholar
• Tanabe-Seiyaku. Pharmaceutical compositions containing 5-phenylbenzylamine derivatives as tachykinin receptor antagonists. JP2004002334; 2004
   Google Scholar
• Tanabe-Seiyaku. Preparation of piperidine derivatives as tachykinin receptor antagonists.JP2007277231; 2007
   Google Scholar
• Tanabe-Seiyaku. Pharmaceutical compositions containing thiomorpholine compound as tachykinin antagonists. JP2008239618; 2008
   Google Scholar
• University of Pennsylvania. Preparation of non-peptide peptidomimetics useful for mimicking or inhibiting the activity of peptides. WO9317032; 1993
   Google Scholar
• University of Pennsylvania. Non-peptide peptidomimetics with affinity for G-protein-linked receptors. WO9511686; 1995
   Google Scholar
• University of Pennsylvania. Preparation of carbohydrate and cyclopeptide mimetics binding to G-protein-linked receptors. US5811512; 1998
   Google Scholar
• University of Pennsylvania. Preparation of non-peptide peptidomimetics amino glycosides as G-protein-linked receptors. US6197963; 2001
   Google Scholar
• Hirschmann R, Nicolaou KC, Pietranico S, Nonpeptidal peptidomimetics with .beta.-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. J Am Chem Soc 1992;114:9217-8
   Web of Science ®Google Scholar
• Hisamitsu. Preparation and formulation of piperidine derivatives as substance P antagonists. WO9630367; 1996
   Google Scholar
• Hisamitsu. Preparation of 3-heterocyclylalkylamino-2-phenylpiperidine derivatives as substance P antagonists. WO01025233; 2001
   Google Scholar
• Saeki M, Sakai M, Saito R, Effects of HSP-117, a novel tachykinin NK1-receptor antagonist, on cisplatin-induced pica as a new evaluation of delayed emesis in rats. Jpn J Pharmacol 2001;86:359-62
   PubMedGoogle Scholar
• Seto S, Tanioka A, Ikeda M, Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists. Bioorg Med Chem Lett 2005;15:1479-84
   PubMedGoogle Scholar
• Kyorin. Preparation of fused bicyclic pyrimidine derivatives as tachykinin antagonists. WO03062245; 2003
   Google Scholar
• Seto S, Tanioka A, Ikeda M, Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists. Bioorg Med Chem 2005;13:5717-32
   PubMedGoogle Scholar
• Kyorin. Process for preparation of 2-(4-acetylpiperazin-1-yl)-6-[3,5-bis(trifluoromethyl)phenylmethyl]-4-(2-methylphenyl)-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one. WO05019225; 2005
   Google Scholar
• Nippon Zoki. Preparation of benzyloxypropylamine derivatives as tachykinin receptor antagonists. WO06106727; 2006
   Google Scholar
• Cappelli A, Giuliani G, Anzini M, Design, synthesis, and structure-affinity relationship studies in NK1 receptor ligands based on azole-fused quinolinecarboxamide moieties. Bioorg Med Chem 2008;16:6850-9
   PubMed Web of Science ®Google Scholar
• Universita degli Studi di Siena. Preparation of heterotricyclic carboxamides as neurokinin-1 (NK1) receptor ligands. WO07074491; 2007
   Google Scholar
• Solvay. N-Triazolylmethylpiperazine derivatives as neurokinin receptor antagonists. US20020065276; 2002
   Google Scholar
• Hesse C, Luntz SP, Siedler H, Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals. Br J Clin Pharmacol 2006;61:414-9
   PubMed Web of Science ®Google Scholar
• Swain CJ, Seward EM, Cascieri MA, Identification of a series of 3-(benzyloxy)-1-azabicyclo-[2.2.2]octane human NK1 antagonists. J Med Chem 1995;38:4793-805
   PubMed Web of Science ®Google Scholar
• Boks GJ, Tollenaere JP, Kroon J. Possible ligand-receptor interactions for NK1 antagonists as observed in their crystal structures. Bioorg Med Chem 1997;5:535-47
   PubMedGoogle Scholar
• Takeuchi Y, Shands EFB, Beusen DD, Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. J Med Chem 1998;41:3609-23
   PubMed Web of Science ®Google Scholar
• Evers A, Klebe G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem 2004;47:5381-92
   PubMed Web of Science ®Google Scholar
• Hafizi S, Chandra P, Cowen J. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations. Br J Psychiatry 2007;191:282-4
   PubMed Web of Science ®Google Scholar